** Gilead Sciences GILD.O shares edging up 0.1% on Thurs ahead of qtrly results after the bell, with investors focused on HIV drug sales

** Analysts expect qtrly rev up ~1.9% to $6.81 bln, adjusted EPS seen at $1.79 vs loss of $1.32 yr-ago, per LSEG

** GILD stock has gained about 15% YTD, outperforming Nasdaq .IXIC, which fell ~12%

** Stock recently traded at ~13 times expected earnings, above its avg forward PE of 11

** In past 30 days, one out of 29 analysts raised EPS estimates for qtr, while one revised downwards

(Reporting by Noel Randewich)

((noel.randewich@thomsonreuters.com))